ASTRAZENECA

ASTRAZENECA is UK Based Pharmaceutical and Bio-Technology Company. In the fight against COVID-19,Astrazeneca is one among World Top 5 Companies which is in advanced phase of Covid-19 testing in collaboration with the University of Oxford and are launching Phase III trials. Headquarters is in UK.

AstraZeneca has annual revenue was 37,417 million USD for year ending Dec-2021 when compared to with 26,617 million USD as on 2020.

AstraZeneca Annual Product Sales was 36,541 million USD for year ending Dec-2021 when compared with 25,890 million USD for year ending Dec-2020.

For year ending Dec-2021, operating income was 1.056 Million USD.

AstraZeneca has 83,100 employees as on 2021 when compared to with 76,100 employees as on 2020 and 70,600 employees as on 2019.

AstraZeneca has total assets are 105,363 million USD as on Dec-2021 when compared to 66,729 million USD as on Dec-2020.

ASTRAZENECA Product Sales split by Disease Area for year ending Dec-2021

Oncology contributed 36% and annual revenue contributed is 13,048 million USD.
BioPharmaceuticals contributed 38% and annual revenue contributed is 8,02 million USD.
Rare Disease contributed 8% annual revenue contributed is 3,070 million USD.
Other Medicines contributed 17% annual revenue contributed is 2,367 million USD.
Covid-19 contributed 11% annual revenue contributed is 4,002 million USD.
Respiratory & Immunology contributed 17% annual revenue contributed is 6,034 million USD.

ASTRAZENECA Product Sales split of 36,541 Million USD by Disease Area for year ending Dec-2021

12,161 Million USD from Emerging Markets
12,000 Million USD from USA.
7,604 Million USD from Europe.
From the rest of the World, it is 4,776 Million USD

Facts About Company

Astrazeneca company acquired Alexion Pharmaceuticals for 39 Billion USD in 2020.

As on 2021, Astrazeneca has 83,100 employees and out of that

15,900 employees are from USA.
8,800 employees are from UK
20,600 employees are from China
6,900 employees are from Sweden
11,400 employees are from Other Europe has
7,100 employees are from Other Asia Pacific
1,100 employees are from Canada and 1,800 employees are from Middle East and Africa and 1,600 employees are from Russia and 3,400 employees are from Japan and 1,000 employees are from Australia and New Zealand

Annual Revenue

ASTRAZENECA Annual Revenues for December-2020 ending is 26.21 Billion USD

Annual Operating Income

3.69 Billion USD for Year ending December-2020

Annual Net Income

ASTRAZENECA Annual Net Income for December-2020 ending is 3.19 Billion USD

Total Current Assets

15,563 Million USD as on Dec 2019

Total Assets

66.73 Billion USD for Year ending December-2020

Total Current Liabilities

18,117 Million USD as on Dec 2019

Total Liabilities

51.09 Billion USD for Year ending December-2020

Total Equity

15.64 Billion USD for Year ending December-2020

Annual Results Summary:

AstraZeneca PLC - Annual Results - Revenue and Net Profit - in Million USD:

Year - Ending	Revenue	Operating Income	Net Profit	EPS (USD)
Dec-2021	37,417	1,056	112	0.08
Dec-2020	26,217	3,694	3,196	2.43
Dec-2019	24,384	1,702	1,335	0.52
Dec-2018	22,090	1,510	2,155	0.85
Dec-2017	22,465	2,292	3,001	1.19

Balance Sheet Summary

AstraZeneca PLC - Balance Sheet Summary - in Million USD:

Astrazeneca Total Assets as on September-2021 was 107,221 Million USD.

Astrazeneca Total Liabilities as on September-2021 was 67,309 Million USD.

Astrazeneca Total Equity as on September-2021 was 39,912 Million USD.

Quarterly Results Summary:

AstraZeneca PLC - Quarterly Results - Revenue and Net Profit - in Million USD:

Quarter - Ending	Revenue	Net Profit
Jun-2022	10,771	360
Mar-2022	11,390	386
Dec-2021	12,011	-292 (Loss)
Sep-2021	9,866	-1,652
Jun-2021	8,220	550
Mar-2021	7,320	1,561
Dec-2020	7,410	1,012
Sep-2020	6,578	651
Jun-2020	6,275	837
Mar-2020	6,354	780
Dec-2019	6,664	313
Sep-2019	6,406	299
Jun-2019	5,823	130
Mar-2019	5,491	593

Comments

Oxford Vaccine Trials again resumed by Astrazeneca

Oxford Vaccine Trials again resumed by Astrazeneca after UK Regulatory Authorities had given permission to go ahead with trials. Post one person undergoing trials had fallen ill, Astrazeneca temporarily paused trials of Oxford Vaccine.

Then again after review, as UK health regulatory authorities had given permission to go ahead with trials, again Oxford Vaccine Trials started.

Russia vaccine and Oxford vaccine are two vaccines related to Covid-19, that are in most advance stages of testing.